SCHEDULE: Viking Global Investors Discloses 4.3% Stake in BioMarin

Viking Global Investors LP and its affiliates report a passive beneficial ownership of 4.3% in BioMarin Pharmaceutical Inc. common stock.

Summary

• Viking Global Investors LP, along with its affiliated entities and executive committee members O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, collectively beneficially own 8,322,179 shares of BioMarin Pharmaceutical Inc. common stock.
• This aggregate ownership represents 4.3% of BioMarin's outstanding common stock.
• The percentage is based on 192,098,751 shares of common stock outstanding as of September 30, 2025, as reported by BioMarin in its Form 10-Q.
• The shares are held across various Viking Global entities, including Viking Global Performance LLC (2.8%), Viking Global Equities II LP (0.1%), Viking Global Equities Master Ltd. (2.8%), Viking Long Fund GP LLC (1.1%), Viking Long Fund Master Ltd. (1.1%), Viking Global Opportunities Parent GP LLC (0.4%), Viking Global Opportunities GP LLC (0.4%), Viking Global Opportunities Portfolio GP LLC (0.4%), and Viking Global Opportunities Liquid Portfolio Sub-Master LP (0.4%).
• All reporting persons have shared voting and shared dispositive power over their respective beneficially owned shares.
• The securities were not acquired and are not held for the purpose of changing or influencing the control of BioMarin, except for activities solely in connection with a nomination under Rule 240.14a-11.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, indicating a neutral sentiment as it does not contain performance updates, strategic changes, or forward-looking statements that would typically influence sentiment.

Future Outlook

NA

Industry Context

This filing reflects a routine disclosure of passive institutional ownership in the biotechnology and pharmaceutical sector. Large investment firms like Viking Global Investors frequently adjust their positions in publicly traded companies, and such disclosures provide transparency into significant holdings without necessarily indicating a change in company strategy or performance.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming Viking Global Investors' continued interest in BioMarin Pharmaceutical Inc. stock.

Key Dates

Keywords

BioMarin Pharmaceutical, Viking Global Investors, Beneficial Ownership, Schedule 13G, Common Stock, Institutional Ownership, Biotechnology, Pharmaceuticals